Valéria de Freitas Dutra1, Vinicius Nunes Cordeiro Leal2, Alessandra Pontillo2. 1. Hematology and Blood Transfusion Division, Clinical and Experimental Oncology Department, Escola Paulista de Medicina, Universidade Federal de São Paulo (EPM/UNIFESP), R. Dr. Diogo de Farias, 824, Vila Clementino, São Paulo, SP, 04037-002, Brazil. valeriafdutra@yahoo.com. 2. Laboratory of Immunogenetics, Department of Immunology, Institute of Biomedical Sciences/ICB, University of São Paulo/USP, Av. Prof. Lineu Prestes, 1730-Butantã, São Paulo, 05508-000, Brazil.
Abstract
BACKGROUND: The inflammasome is a cytosolic multi-protein complex responsible for the proteolytic maturation of pro-inflammatory cytokines IL-1ß and IL-18 and of gasdermin-D, which mediates membrane pore formation and the cytokines release, or eventually a lytic cell death known as pyroptosis. Inflammation has long been accepted as a key component of hematologic conditions, either oncological or benign diseases. OBJECTIVES: This study aims to review the current knowledge about the contribution of inflammasome in hematologic diseases. We attempted to depict the participation of specific inflammasome receptors, and the possible cell-specific consequence of complex activation, as well as the use of anti-inflammasome therapies. METHODS: We performed a keyword-based search in public databases (Pubmed.gov, ClinicalTrials.gov.). CONCLUSION: Different blood cells variably express inflammasome components. Considering the immunosuppression associated with both the disease and the treatment of some hematologic diseases, and a microenvironment that allows neoplastic cell proliferation, inflammasomes could be a link between innate immunity and disease progression, as well as an interesting therapeutic target.
BACKGROUND: The inflammasome is a cytosolic multi-protein complex responsible for the proteolytic maturation of pro-inflammatory cytokines IL-1ß and IL-18 and of gasdermin-D, which mediates membrane pore formation and the cytokines release, or eventually a lytic cell death known as pyroptosis. Inflammation has long been accepted as a key component of hematologic conditions, either oncological or benign diseases. OBJECTIVES: This study aims to review the current knowledge about the contribution of inflammasome in hematologic diseases. We attempted to depict the participation of specific inflammasome receptors, and the possible cell-specific consequence of complex activation, as well as the use of anti-inflammasome therapies. METHODS: We performed a keyword-based search in public databases (Pubmed.gov, ClinicalTrials.gov.). CONCLUSION: Different blood cells variably express inflammasome components. Considering the immunosuppression associated with both the disease and the treatment of some hematologic diseases, and a microenvironment that allows neoplastic cell proliferation, inflammasomes could be a link between innate immunity and disease progression, as well as an interesting therapeutic target.
Authors: Lola Rodríguez-Ruiz; Juan M Lozano-Gil; Christophe Lachaud; Pablo Mesa-Del-Castillo; María L Cayuela; Diana García-Moreno; Ana B Pérez-Oliva; Victoriano Mulero Journal: Trends Immunol Date: 2020-11-05 Impact factor: 16.687
Authors: Seth L Masters; Motti Gerlic; Donald Metcalf; Simon Preston; Marc Pellegrini; Joanne A O'Donnell; Kate McArthur; Tracey M Baldwin; Stephane Chevrier; Cameron J Nowell; Louise H Cengia; Katya J Henley; Janelle E Collinge; Daniel L Kastner; Lionel Feigenbaum; Douglas J Hilton; Warren S Alexander; Benjamin T Kile; Ben A Croker Journal: Immunity Date: 2012-12-06 Impact factor: 31.745